{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:26:58Z","timestamp":1794324418889,"version":"4.9.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent major advances in developing effective vaccines against toxoplasmosis, finding new protective vaccination strategies remains a challenging and elusive goal as it is critical to prevent the disease. Over the past few years, various experimental approaches have shown that developing an effective vaccine against <jats:italic>T. gondii<\/jats:italic> is achievable. However, more remains unknown due to its complicated life cycle, difficulties in clinical translation, and lack of a standardized platform. This minireview summarizes the recent advances in the development of <jats:italic>T. gondii<\/jats:italic> vaccines and the main obstacles to developing a safe, effective and durable <jats:italic>T. gondii<\/jats:italic> vaccine. The successes and failures in developing and testing vaccine candidates for the <jats:italic>T. gondii<\/jats:italic> vaccine are also discussed, which may facilitate the future development of <jats:italic>T. gondii<\/jats:italic> vaccines.<\/jats:p>","DOI":"10.1038\/s41541-022-00563-0","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T02:02:24Z","timestamp":1667181744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Toxoplasmosis vaccines: what we have and where to go?"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-8969","authenticated-orcid":false,"given":"Yizhuo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-4639","authenticated-orcid":false,"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9855-7154","authenticated-orcid":false,"given":"Shaohong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-2946","authenticated-orcid":false,"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"563_CR1","doi-asserted-by":"publisher","unstructured":"Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O. & Montoya, J. G. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin. Microbiol. Rev. https:\/\/doi.org\/10.1128\/cmr.00057-17 (2018).","DOI":"10.1128\/cmr.00057-17"},{"key":"563_CR2","doi-asserted-by":"publisher","unstructured":"R\u00e9my, V., Z\u00f6llner, Y. & Heckmann, U. Vaccination: the cornerstone of an efficient healthcare system. J. Mark. Access. Health Policy https:\/\/doi.org\/10.3402\/jmahp.v3.27041 (2015).","DOI":"10.3402\/jmahp.v3.27041"},{"key":"563_CR3","doi-asserted-by":"publisher","unstructured":"Chu, K. B. & Quan, F. S. Advances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development. Vaccines (Basel) https:\/\/doi.org\/10.3390\/vaccines9050413 (2021).","DOI":"10.3390\/vaccines9050413"},{"key":"563_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.actatropica.2012.08.013","volume":"124","author":"TA Costa-Silva","year":"2012","unstructured":"Costa-Silva, T. A., Borges, M. M., Galhardo, C. S. & Pereira-Chioccola, V. L. Immunization with excreted\/secreted proteins in AS\/n mice activating cellular and humoral response against Toxoplasma gondii infection. Acta Trop. 124, 203\u2013209 (2012).","journal-title":"Acta Trop."},{"key":"563_CR5","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1007\/s00436-013-3571-4","volume":"112","author":"Y Wang","year":"2013","unstructured":"Wang, Y., Zhang, D., Wang, G., Yin, H. & Wang, M. Immunization with excreted-secreted antigens reduces tissue cyst formation in pigs. Parasitol. Res. 112, 3835\u20133842 (2013).","journal-title":"Parasitol. Res."},{"key":"563_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.34172\/apb.2021.066","volume":"11","author":"E Meshkini","year":"2021","unstructured":"Meshkini, E., Aminpour, A., Hazrati Tappeh, K., Seyyedi, S. & Shokri, M. Evaluation of adjuvant effectiveness of alum-propranolol mixture on the immunogenicity of excreted\/secreted antigens of Toxoplasma gondii RH strain. Adv. Pharm. Bull. 11, 570\u2013577 (2021).","journal-title":"Adv. Pharm. Bull."},{"key":"563_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vetpar.2009.02.026","volume":"163","author":"JP Dubey","year":"2009","unstructured":"Dubey, J. P. Toxoplasmosis in sheep-the last 20 years. Vet. Parasitol. 163, 1\u201314 (2009).","journal-title":"Vet. Parasitol."},{"key":"563_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2307\/3283610","volume":"79","author":"A Freyre","year":"1993","unstructured":"Freyre, A., Choromanski, L., Fishback, J. L. & Popiel, I. Immunization of cats with tissue cysts, bradyzoites, and tachyzoites of the T-263 strain of Toxoplasma gondii. J. Parasitol. 79, 716\u2013719 (1993).","journal-title":"J. Parasitol."},{"key":"563_CR9","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1016\/j.vaccine.2019.05.083","volume":"37","author":"FK Loh","year":"2019","unstructured":"Loh, F. K., Nathan, S., Chow, S. C. & Fang, C. M. Vaccination challenges and strategies against long-lived Toxoplasma gondii. Vaccine 37, 3989\u20134000 (2019).","journal-title":"Vaccine"},{"key":"563_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37671-8","volume":"9","author":"C Ramakrishnan","year":"2019","unstructured":"Ramakrishnan, C. et al. An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats. Sci. Rep. 9, 1474 (2019).","journal-title":"Sci. Rep."},{"key":"563_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/infdis\/jiy211","volume":"218","author":"JL Wang","year":"2018","unstructured":"Wang, J. L. et al. Live attenuated Pru:\u0394cdpk2 strain of toxoplasma gondii protects against acute, chronic, and congenital toxoplasmosis. J. Infect. Dis. 218, 768\u2013777 (2018).","journal-title":"J. Infect. Dis."},{"key":"563_CR12","doi-asserted-by":"publisher","unstructured":"Wang, L., Tang, D., Yang, C., Yang, J. & Fang, R. Toxoplasma gondii ADSL knockout provides excellent immune protection against a variety of strains. Vaccines (Basel) https:\/\/doi.org\/10.3390\/vaccines8010016 (2020).","DOI":"10.3390\/vaccines8010016"},{"key":"563_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fcimb.2017.00142","volume":"7","author":"P Czarnewski","year":"2017","unstructured":"Czarnewski, P., Ara\u00fajo, E. C. B., Oliveira, M. C., Mineo, T. W. P. & Silva, N. M. Recombinant TgHSP70 immunization protects against Toxoplasma gondii brain cyst formation by enhancing inducible nitric oxide expression. Front. Cell Infect. Microbiol. 7, 142 (2017).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"563_CR14","doi-asserted-by":"publisher","first-page":"lqaa048","DOI":"10.1093\/nargab\/lqaa048","volume":"2","author":"OS Onile","year":"2020","unstructured":"Onile, O. S., Ojo, G. J., Oyeyemi, B. F., Agbowuro, G. O. & Fadahunsi, A. I. Development of multiepitope subunit protein vaccines against Toxoplasma gondii using an immunoinformatics approach. NAR Genom. Bioinform. 2, lqaa048 (2020).","journal-title":"NAR Genom. Bioinform."},{"key":"563_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.7774\/cevr.2018.7.1.24","volume":"7","author":"M Foroutan","year":"2018","unstructured":"Foroutan, M. & Ghaffarifar, F. Calcium-dependent protein kinases are potential targets for Toxoplasma gondii vaccine. Clin. Exp. Vaccin. Res. 7, 24\u201336 (2018).","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"563_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7774\/cevr.2020.9.2.146","volume":"9","author":"H Majidiani","year":"2020","unstructured":"Majidiani, H. et al. In-depth computational analysis of calcium-dependent protein kinase 3 of Toxoplasma gondii provides promising targets for vaccination. Clin. Exp. Vaccin. Res. 9, 146\u2013158 (2020).","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"563_CR17","doi-asserted-by":"publisher","first-page":"104764","DOI":"10.1016\/j.micpath.2021.104764","volume":"153","author":"S Dodangeh","year":"2021","unstructured":"Dodangeh, S. et al. Protective efficacy by a novel multi-epitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB\/c mice. Micro. Pathog. 153, 104764 (2021).","journal-title":"Micro. Pathog."},{"key":"563_CR18","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1645\/20-157","volume":"107","author":"RC Warner","year":"2021","unstructured":"Warner, R. C., Chapman, R. C., Davis, B. N. & Davis, P. H. Review of dna vaccine approaches against the parasite Toxoplasma gondii. J. Parasitol. 107, 882\u2013903 (2021).","journal-title":"J. Parasitol."},{"key":"563_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.vetpar.2011.06.010","volume":"183","author":"E Hiszczy\u0144ska-Sawicka","year":"2011","unstructured":"Hiszczy\u0144ska-Sawicka, E. et al. Modulation of immune response to Toxoplasma gondii in sheep by immunization with a DNA vaccine encoding ROP1 antigen as a fusion protein with ovine CD154. Vet. Parasitol. 183, 72\u201378 (2011).","journal-title":"Vet. Parasitol."},{"key":"563_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.4269\/ajtmh.12-0727","volume":"88","author":"S Parthasarathy","year":"2013","unstructured":"Parthasarathy, S., Fong, M. Y., Ramaswamy, K. & Lau, Y. L. Protective immune response in BALB\/c mice induced by DNA vaccine of the ROP8 gene of Toxoplasma gondii. Am. J. Trop. Med. Hyg. 88, 883\u2013887 (2013).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"563_CR21","doi-asserted-by":"publisher","first-page":"10782","DOI":"10.1002\/jcp.27747","volume":"234","author":"P Alizadeh","year":"2019","unstructured":"Alizadeh, P. et al. IL-17 and IL-22 elicited by a DNA vaccine encoding ROP13 associated with protection against Toxoplasma gondii in BALB\/c mice. J. Cell Physiol. 234, 10782\u201310788 (2019).","journal-title":"J. Cell Physiol."},{"key":"563_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1128\/CVI.00312-10","volume":"18","author":"ZG Yuan","year":"2011","unstructured":"Yuan, Z. G. et al. Protective immunity induced by Toxoplasma gondii rhoptry protein 16 against toxoplasmosis in mice. Clin. Vaccin. immunol. 18, 119\u2013124 (2011).","journal-title":"Clin. Vaccin. immunol."},{"key":"563_CR23","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1016\/j.vaccine.2011.06.110","volume":"29","author":"ZG Yuan","year":"2011","unstructured":"Yuan, Z. G. et al. Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18. Vaccine 29, 6614\u20136619 (2011).","journal-title":"Vaccine"},{"key":"563_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.actatropica.2017.09.007","volume":"176","author":"WB Yang","year":"2017","unstructured":"Yang, W. B. et al. Vaccination with a DNA vaccine encoding Toxoplasma gondii ROP54 induces protective immunity against toxoplasmosis in mice. Acta Trop. 176, 427\u2013432 (2017).","journal-title":"Acta Trop."},{"key":"563_CR25","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.4269\/ajtmh.16-0548","volume":"96","author":"XT Ching","year":"2017","unstructured":"Ching, X. T., Fong, M. Y. & Lau, Y. L. Evaluation of the protective effect of deoxyribonucleic acid vaccines encoding granule antigen 2 and 5 against acute toxoplasmosis in BALB\/c mice. Am. J. Trop. Med. Hyg. 96, 1441\u20131447 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"563_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3389\/fimmu.2019.00418","volume":"10","author":"B Zheng","year":"2019","unstructured":"Zheng, B. et al. GRA24-based DNA vaccine prolongs survival in mice challenged with a virulent Toxoplasma gondii strain. Front. Immunol. 10, 418 (2019).","journal-title":"Front. Immunol."},{"key":"563_CR27","doi-asserted-by":"publisher","first-page":"105696","DOI":"10.1016\/j.mimet.2019.105696","volume":"165","author":"F Rezaei","year":"2019","unstructured":"Rezaei, F. et al. A systematic review on the role of GRA proteins of Toxoplasma gondii in host immunization. J. Microbiol. Methods 165, 105696 (2019).","journal-title":"J. Microbiol. Methods"},{"key":"563_CR28","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1016\/j.vaccine.2014.03.042","volume":"32","author":"ZY Li","year":"2014","unstructured":"Li, Z. Y. et al. Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice. Vaccine 32, 3058\u20133065 (2014).","journal-title":"Vaccine"},{"key":"563_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7774\/cevr.2018.7.2.93","volume":"7","author":"M Foroutan","year":"2018","unstructured":"Foroutan, M., Zaki, L. & Ghaffarifar, F. Recent progress in microneme-based vaccines development against Toxoplasma gondii. Clin. Exp. Vaccin. Res. 7, 93\u2013103 (2018).","journal-title":"Clin. Exp. Vaccin. Res"},{"key":"563_CR30","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.cimid.2020.101414","volume":"69","author":"AS Pagheh","year":"2020","unstructured":"Pagheh, A. S. et al. Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review. Comp. Immunol. Microbiol. Infect. Dis. 69, 101414 (2020).","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"563_CR31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"MA Kutzler","year":"2008","unstructured":"Kutzler, M. A. & Weiner, D. B. DNA vaccines: ready for prime time. Nat. Rev. Genet. 9, 776\u2013788 (2008).","journal-title":"Nat. Rev. Genet"},{"key":"563_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21775\/cimb.022.079","volume":"22","author":"AI Myhr","year":"2017","unstructured":"Myhr, A. I. DNA vaccines: regulatory considerations and safety aspects. Curr. Issues Mol. Biol. 22, 79\u201388 (2017).","journal-title":"Curr. Issues Mol. Biol."},{"key":"563_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73210-0","volume":"10","author":"K El Bissati","year":"2020","unstructured":"El Bissati, K. et al. Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice. Sci. Rep. 10, 16984 (2020).","journal-title":"Sci. Rep."},{"key":"563_CR34","doi-asserted-by":"publisher","first-page":"e85955","DOI":"10.1172\/jci.insight.85955","volume":"1","author":"K El Bissati","year":"2016","unstructured":"El Bissati, K. et al. Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight 1, e85955 (2016).","journal-title":"JCI Insight"},{"key":"563_CR35","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.vaccine.2014.03.092","volume":"32","author":"K El Bissati","year":"2014","unstructured":"El Bissati, K. et al. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine 32, 3243\u20133248 (2014).","journal-title":"Vaccine"},{"key":"563_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0024-6","volume":"2","author":"K El Bissati","year":"2017","unstructured":"El Bissati, K. et al. Protein nanovaccine confers robust immunity against Toxoplasma. npj Vaccines 2, 24 (2017).","journal-title":"npj Vaccines"},{"key":"563_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/14712598.2018.1413086","volume":"18","author":"Y Li","year":"2018","unstructured":"Li, Y. & Zhou, H. Moving towards improved vaccines for Toxoplasma gondii. Expert. Opin. Biol. Ther. 18, 273\u2013280 (2018).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"563_CR38","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1016\/j.vaccine.2018.08.068","volume":"36","author":"M Roozbehani","year":"2018","unstructured":"Roozbehani, M. et al. Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection. Vaccine 36, 6124\u20136132 (2018).","journal-title":"Vaccine"},{"key":"563_CR39","doi-asserted-by":"crossref","unstructured":"Luo, F. et al. Induction of protective immunity against toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle. Front. Microbiol. 8, 605 (2017).","DOI":"10.3389\/fmicb.2017.00605"},{"key":"563_CR40","doi-asserted-by":"publisher","first-page":"585354","DOI":"10.3389\/fimmu.2020.585354","volume":"11","author":"O Sharma","year":"2020","unstructured":"Sharma, O., Sultan, A. A., Ding, H. & Triggle, C. R. A review of the progress and challenges of developing a vaccine for COVID-19. Front. Immunol. 11, 585354 (2020).","journal-title":"Front. Immunol."},{"key":"563_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","volume":"131","author":"EH Pilkington","year":"2021","unstructured":"Pilkington, E. H. et al. From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 131, 16\u201340 (2021).","journal-title":"Acta Biomater."},{"key":"563_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","volume":"65","author":"N Pardi","year":"2020","unstructured":"Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14\u201320 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"563_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.plipres.2011.05.002","volume":"50","author":"Y Maeda","year":"2011","unstructured":"Maeda, Y. & Kinoshita, T. Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins. Prog. Lipid Res. 50, 411\u2013424 (2011).","journal-title":"Prog. Lipid Res"},{"key":"563_CR44","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.4049\/jimmunol.179.2.1129","volume":"179","author":"F Debierre-Grockiego","year":"2007","unstructured":"Debierre-Grockiego, F. et al. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii. J. Immunol. 179, 1129\u20131137 (2007).","journal-title":"J. Immunol."},{"key":"563_CR45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrd3012","volume":"9","author":"RD Astronomo","year":"2010","unstructured":"Astronomo, R. D. & Burton, D. R. Carbohydrate vaccines: developing sweet solutions to sticky situations. Nat. Rev. Drug Discov. 9, 308\u2013324 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"563_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/gast.2001.26263","volume":"121","author":"G van Niel","year":"2001","unstructured":"van Niel, G. et al. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 121, 337\u2013349 (2001).","journal-title":"Gastroenterology"},{"key":"563_CR47","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/ni854","volume":"3","author":"C Th\u00e9ry","year":"2002","unstructured":"Th\u00e9ry, C. et al. Indirect activation of na\u00efve CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 3, 1156\u20131162 (2002).","journal-title":"Nat. Immunol."},{"key":"563_CR48","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2147\/IJN.S151110","volume":"13","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Characterization of exosomes derived from Toxoplasma gondii and their functions in modulating immune responses. Int. J. Nanomed. 13, 467\u2013477 (2018).","journal-title":"Int. J. Nanomed."},{"key":"563_CR49","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1128\/IAI.72.7.4127-4137.2004","volume":"72","author":"F Aline","year":"2004","unstructured":"Aline, F., Bout, D., Amigorena, S., Roingeard, P. & Dimier-Poisson, I. Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection. Infect. Immun. 72, 4127\u20134137 (2004).","journal-title":"Infect. Immun."},{"key":"563_CR50","doi-asserted-by":"publisher","first-page":"711565","DOI":"10.3389\/fimmu.2021.711565","volume":"12","author":"P Santos","year":"2021","unstructured":"Santos, P. & Almeida, F. Exosome-based vaccines: history, current state, and clinical trials. Front. Immunol. 12, 711565 (2021).","journal-title":"Front. Immunol."},{"key":"563_CR51","doi-asserted-by":"publisher","first-page":"104888","DOI":"10.1016\/j.micpath.2021.104888","volume":"155","author":"N Yektaeian","year":"2021","unstructured":"Yektaeian, N., Malekpour, A., Atapour, A., Davoodi, T. & Hatam, G. Genetic immunization against toxoplasmosis: a review article. Micro. Pathog. 155, 104888 (2021).","journal-title":"Micro. Pathog."},{"key":"563_CR52","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s13071-020-04445-z","volume":"13","author":"M Attias","year":"2020","unstructured":"Attias, M. et al. The life-cycle of Toxoplasma gondii reviewed using animations. Parasit. Vectors 13, 588 (2020).","journal-title":"Parasit. Vectors"},{"key":"563_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1745-7580-6-12","volume":"6","author":"H Cong","year":"2010","unstructured":"Cong, H. et al. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+ T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 6, 12 (2010).","journal-title":"Immunome Res."},{"key":"563_CR54","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/infdis\/172.6.1561","volume":"172","author":"DK Howe","year":"1995","unstructured":"Howe, D. K. & Sibley, L. D. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J. Infect. Dis. 172, 1561\u20131566 (1995).","journal-title":"J. Infect. Dis."},{"key":"563_CR55","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.pt.2005.08.001","volume":"21","author":"JP Saeij","year":"2005","unstructured":"Saeij, J. P., Boyle, J. P. & Boothroyd, J. C. Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. Trends Parasitol. 21, 476\u2013481 (2005).","journal-title":"Trends Parasitol."},{"key":"563_CR56","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ijpara.2011.01.005","volume":"41","author":"A Khan","year":"2011","unstructured":"Khan, A. et al. Genetic analyses of atypical Toxoplasma gondii strains reveal a fourth clonal lineage in North America. Int. J. Parasitol. 41, 645\u2013655 (2011).","journal-title":"Int. J. Parasitol."},{"key":"563_CR57","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1073\/pnas.1203190109","volume":"109","author":"C Su","year":"2012","unstructured":"Su, C. et al. Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages. Proc. Natl Acad. Sci. USA 109, 5844\u20135849 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"563_CR58","doi-asserted-by":"publisher","first-page":"e02280","DOI":"10.1128\/mBio.02280-14","volume":"6","author":"KD Jensen","year":"2015","unstructured":"Jensen, K. D. et al. Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5\/ROP18 allelic combination. mBio 6, e02280 (2015).","journal-title":"mBio"},{"key":"563_CR59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0020-7519(00)00151-X","volume":"31","author":"A Dao","year":"2001","unstructured":"Dao, A., Fortier, B., Soete, M., Plenat, F. & Dubremetz, J. F. Successful reinfection of chronically infected mice by a different Toxoplasma gondii genotype. Int. J. Parasitol. 31, 63\u201365 (2001).","journal-title":"Int. J. Parasitol."},{"key":"563_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/infdis\/jiy170","volume":"218","author":"G Feng","year":"2018","unstructured":"Feng, G. et al. Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional antibodies to multiple parasite strains. J. Infect. Dis. 218, 35\u201343 (2018).","journal-title":"J. Infect. Dis."},{"key":"563_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0183-5","volume":"12","author":"U Terheggen","year":"2014","unstructured":"Terheggen, U. et al. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines. BMC Med. 12, 183 (2014).","journal-title":"BMC Med."},{"key":"563_CR62","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.parint.2014.05.003","volume":"63","author":"C Padr\u00e3o Jda","year":"2014","unstructured":"Padr\u00e3o Jda, C., Cabral, G. R., da Silva Mde, F., Seabra, S. H. & DaMatta, R. A. Toxoplasma gondii infection of activated J774-A1 macrophages causes inducible nitric oxide synthase degradation by the proteasome pathway. Parasitol. Int. 63, 659\u2013663 (2014).","journal-title":"Parasitol. Int."},{"key":"563_CR63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41579-021-00518-7","volume":"19","author":"SK Matta","year":"2021","unstructured":"Matta, S. K., Rinkenberger, N., Dunay, I. R. & Sibley, L. D. Toxoplasma gondii infection and its implications within the central nervous system. Nat. Rev. Microbiol. 19, 467\u2013480 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"563_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.chom.2016.06.006","volume":"20","author":"P Olias","year":"2016","unstructured":"Olias, P., Etheridge, R. D., Zhang, Y., Holtzman, M. J. & Sibley, L. D. Toxoplasma effector recruits the Mi-2\/NuRD complex to repress STAT1 transcription and block IFN-\u03b3-dependent gene expression. Cell Host Microbe 20, 72\u201382 (2016).","journal-title":"Cell Host Microbe"},{"key":"563_CR65","doi-asserted-by":"publisher","unstructured":"Chen, L. et al. The Toxoplasma gondii virulence factor ROP16 acts in cis and trans, and suppresses T cell responses. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20181757 (2020).","DOI":"10.1084\/jem.20181757"},{"key":"563_CR66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.chom.2014.04.002","volume":"15","author":"RD Etheridge","year":"2014","unstructured":"Etheridge, R. D. et al. The Toxoplasma pseudokinase ROP5 forms complexes with ROP18 and ROP17 kinases that synergize to control acute virulence in mice. Cell Host Microbe 15, 537\u2013550 (2014).","journal-title":"Cell Host Microbe"},{"key":"563_CR67","doi-asserted-by":"publisher","unstructured":"Nadipuram, S. M. et al. In vivo biotinylation of the toxoplasma parasitophorous vacuole reveals novel dense granule proteins important for parasite growth and pathogenesis. mBio https:\/\/doi.org\/10.1128\/mBio.00808-16 (2016).","DOI":"10.1128\/mBio.00808-16"},{"key":"563_CR68","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.chom.2015.04.003","volume":"17","author":"DA Gold","year":"2015","unstructured":"Gold, D. A. et al. The toxoplasma dense granule proteins GRA17 and GRA23 mediate the movement of small molecules between the host and the parasitophorous vacuole. Cell Host Microbe 17, 642\u2013652 (2015).","journal-title":"Cell Host Microbe"},{"key":"563_CR69","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s00436-020-06815-z","volume":"119","author":"TT Li","year":"2020","unstructured":"Li, T. T. et al. Effect of deletion of gra17 and gra23 genes on the growth, virulence, and immunogenicity of type II Toxoplasma gondii. Parasitol. Res. 119, 2907\u20132916 (2020).","journal-title":"Parasitol. Res."},{"key":"563_CR70","doi-asserted-by":"publisher","first-page":"685913","DOI":"10.3389\/fcell.2021.685913","volume":"9","author":"L Yao","year":"2021","unstructured":"Yao, L. et al. Toxoplasma gondii type-I ROP18 targeting human E3 ligase TRIM21 for immune escape. Front. Cell Dev. Biol. 9, 685913 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"563_CR71","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41564-019-0431-8","volume":"4","author":"L Braun","year":"2019","unstructured":"Braun, L. et al. The Toxoplasma effector TEEGR promotes parasite persistence by modulating NF-\u03baB signalling via EZH2. Nat. Microbiol. 4, 1208\u20131220 (2019).","journal-title":"Nat. Microbiol."},{"key":"563_CR72","unstructured":"Bernhagen, Jr & Bucala R. Mif Family Cytokines in Innate Immunity and Homeostasis. (Springer International Publishing: Imprint: Springer, 2017)."},{"key":"563_CR73","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3389\/fimmu.2019.01995","volume":"10","author":"S Ghosh","year":"2019","unstructured":"Ghosh, S., Jiang, N., Farr, L., Ngobeni, R. & Moonah, S. Parasite-produced MIF cytokine: role in immune evasion, invasion, and pathogenesis. Front. Immunol. 10, 1995 (2019).","journal-title":"Front. Immunol."},{"key":"563_CR74","doi-asserted-by":"publisher","unstructured":"Tu, V. et al. Enrichment and proteomic characterization of the cyst wall from in vitro Toxoplasma gondii cysts. mBio https:\/\/doi.org\/10.1128\/mBio.00469-19 (2019).","DOI":"10.1128\/mBio.00469-19"},{"key":"563_CR75","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.cell.2019.12.013","volume":"180","author":"BS Waldman","year":"2020","unstructured":"Waldman, B. S. et al. Identification of a master regulator of differentiation in toxoplasma. Cell 180, 359\u2013372.e316 (2020).","journal-title":"Cell"},{"key":"563_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0353-9","volume":"51","author":"M Sasai","year":"2019","unstructured":"Sasai, M. & Yamamoto, M. Innate, adaptive, and cell-autonomous immunity against Toxoplasma gondii infection. Exp. Mol. Med. 51, 1\u201310 (2019).","journal-title":"Exp. Mol. Med."},{"key":"563_CR77","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.mib.2011.07.002","volume":"14","author":"JC Howard","year":"2011","unstructured":"Howard, J. C., Hunn, J. P. & Steinfeldt, T. The IRG protein-based resistance mechanism in mice and its relation to virulence in Toxoplasma gondii. Curr. Opin. Microbiol. 14, 414\u2013421 (2011).","journal-title":"Curr. Opin. Microbiol."},{"key":"563_CR78","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1172\/JCI136226","volume":"130","author":"XY Zhao","year":"2020","unstructured":"Zhao, X. Y. & Ewald, S. E. The molecular biology and immune control of chronic Toxoplasma gondii infection. J. Clin. Invest. 130, 3370\u20133380 (2020).","journal-title":"J. Clin. Invest"},{"key":"563_CR79","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.4049\/jimmunol.165.3.1498","volume":"165","author":"CS Subauste","year":"2000","unstructured":"Subauste, C. S. & Wessendarp, M. Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites: dendritic cell activation after infection with viable parasites results in CD28 and CD40 ligand signaling that controls IL-12-dependent and -independent T cell production of IFN-gamma. J. Immunol. 165, 1498\u20131505 (2000).","journal-title":"J. Immunol."},{"key":"563_CR80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.vetpar.2005.01.006","volume":"129","author":"JL Garcia","year":"2005","unstructured":"Garcia, J. L. et al. Partial protection against tissue cysts formation in pigs vaccinated with crude rhoptry proteins of Toxoplasma gondii. Vet. Parasitol. 129, 209\u2013217 (2005).","journal-title":"Vet. Parasitol."},{"key":"563_CR81","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1080\/21645515.2021.1934354","volume":"17","author":"GG Guerrero Manriquez","year":"2021","unstructured":"Guerrero Manriquez, G. G. & Tuero, I. Adjuvants: friends in vaccine formulations against infectious diseases. Hum. Vaccines Immunother. 17, 3539\u20133550 (2021).","journal-title":"Hum. Vaccines Immunother."},{"key":"563_CR82","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.pt.2018.08.007","volume":"34","author":"JM Inclan-Rico","year":"2018","unstructured":"Inclan-Rico, J. M. & Siracusa, M. C. First responders: innate immunity to helminths. Trends Parasitol. 34, 861\u2013880 (2018).","journal-title":"Trends Parasitol."},{"key":"563_CR83","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0169-4758(93)90236-9","volume":"9","author":"D Buxton","year":"1993","unstructured":"Buxton, D. Toxoplasmosis: the first commercial vaccine. Parasitol. Today 9, 335\u2013337 (1993).","journal-title":"Parasitol. Today"},{"key":"563_CR84","doi-asserted-by":"crossref","unstructured":"Sander, V., Angel, S. O. & Clemente, M. In Prospects of Plant-Based Vaccines in Veterinary Medicine (ed. MacDonald, J.), 89\u2013120. (Springer International Publishing, 2018).","DOI":"10.1007\/978-3-319-90137-4_4"},{"key":"563_CR85","doi-asserted-by":"crossref","unstructured":"Sacks D. L., Peters N. C., Bethony J. M. In The Vaccine Book, 2nd edn. (eds. Bloom, B. R. & Lambert, P.-H.), Ch. 17, 331\u2013360. (Academic Press, 2016).","DOI":"10.1016\/B978-0-12-802174-3.00017-5"},{"key":"563_CR86","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fcimb.2020.00288","volume":"10","author":"VA Sander","year":"2020","unstructured":"Sander, V. A. et al. Use of veterinary vaccines for livestock as a strategy to control foodborne parasitic diseases. Front. Cell Infect. Microbiol. 10, 288 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"563_CR87","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00019053-200826030-00004","volume":"26","author":"SY Kim","year":"2008","unstructured":"Kim, S. Y. & Goldie, S. J. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. PharmacoEconomics 26, 191\u2013215 (2008).","journal-title":"PharmacoEconomics"},{"key":"563_CR88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tpb.2015.08.003","volume":"105","author":"D Sykes","year":"2015","unstructured":"Sykes, D. & Rycht\u00e1\u0159, J. A game-theoretic approach to valuating toxoplasmosis vaccination strategies. Theor. Popul. Biol. 105, 33\u201338 (2015).","journal-title":"Theor. Popul. Biol."},{"key":"563_CR89","doi-asserted-by":"publisher","first-page":"100380","DOI":"10.1016\/j.epidem.2019.100380","volume":"30","author":"AA Bona\u010di\u0107 Marinovi\u0107","year":"2019","unstructured":"Bona\u010di\u0107 Marinovi\u0107, A. A. et al. Prospects of toxoplasmosis control by cat vaccination. Epidemics 30, 100380 (2019).","journal-title":"Epidemics"},{"key":"563_CR90","doi-asserted-by":"publisher","first-page":"e00053","DOI":"10.1016\/j.fawpar.2019.e00053","volume":"15","author":"EA Innes","year":"2019","unstructured":"Innes, E. A., Hamilton, C., Garcia, J. L., Chryssafidis, A. & Smith, D. A one health approach to vaccines against Toxoplasma gondii. Food Waterborne Parasitol. 15, e00053 (2019).","journal-title":"Food Waterborne Parasitol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00563-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T03:02:37Z","timestamp":1667185357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00563-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00563-0","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"2 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}